- ResMed Inc RMD has agreed to acquire privately-held MEDIFOX DAN, a Germany-based provider of out-of-hospital software solutions, from Hg, a software and services investor.
- MEDIFOX DAN's clinical, financial, and operational solutions are similar to ResMed's U.S. SaaS brands, MatrixCare and Brightree.
- MEDIFOX DAN's German customer base is complementary to the customers of ResMed's U.S.-based SaaS business.
- Related: ResMed's Q3 Earnings Short Of Expectations, Profit Margins Contract.
- The acquisition of MEDIFOX DAN builds on ResMed's existing business in Germany as a provider of cloud-connected medical devices for patients with sleep apnea and other respiratory conditions.
- ResMed will acquire MEDIFOX DAN for approximately $1.0 billion (€950 million), which ResMed expects to fund with its existing credit facilities.
- In 2021, MEDIFOX DAN's pro forma net revenue was approximately $83 million, with a pro forma adjusted EBITDA of approximately $35 million.
- The transaction is expected to be accretive to ResMed's non-GAAP EPS.
- ResMed will retain MEDIFOX DAN's employees, management structure, locations, and business processes. MEDIFOX DAN co-Managing Directors Thorsten Schliebe and Christian Städtler will continue in their current roles, reporting to ResMed SaaS President Bobby Ghoshal.
- Price Action: RMD shares closed at $202.39 on Monday.
- Photo by Capri23auto from Pixabay
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in